source
- GSK and Ionis receive FDA nod for Hibsago, a potential functional cure for chronic hepatitis BThe U.S. Food and Drug Administration has cleared Hibsago, a collaborative product of GSK and Ionis, as the first therapy of its kind aimed at chronic hepatitis B. The medicine is to be added to s…
- FDA week: HHS launches vaccine injury study, midterms may reshape oversight committees, and patent thickets threaten genericsThe Department of Health and Human Services announced a new agency‑wide effort to examine and address injuries that may be linked to vaccines. The initiative will coordinate research across FDA and…